Muscular dystrophy

September 26, 2017

Molecular therapy for muscle atrophy and wasting: Fluoxetine, an anti-depressant drug, increases the expression of FGF19 and its receptor ß-Klotho, phosphorylates ERK1/2 and S6K1, decreases the expression of tumor suppressors genes, promotes regeneration of muscle cells and hypertrophy of skeletal muscle, and reverses muscular atrophy and wasting via up regulation of its target gene, 26/September/2017, 6.24 am

Molecular therapy for muscle atrophy and wasting: Fluoxetine, an anti-depressant drug, increases the expression of FGF19 and its receptor ß-Klotho, phosphorylates ERK1/2 and S6K1, decreases the expression of tumor suppressors genes, promotes regeneration of muscle cells and hypertrophy of skeletal muscle, and reverses muscular atrophy and wasting via up regulation of its target gene, 26/September/2017, 6.24 am https://genomediscovery.org/wp-content/uploads/2017/09/Fluoxetine-protects-against-muscular-dystrophy-through-activation-of-FGF19-pathway1.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2017/09/Fluoxetine-protects-against-muscular-dystrophy-through-activation-of-FGF19-pathway1.jpg September 26, 2017 September 26, 2017

Introduction: What they say A study from Department of Biology, University of Bergen, Bergen, Norway; and Univ-Lyon, CarMeN Laboratory, INSERM 1060, INRA 1397, Université Claude Bernard Lyon, INSA Lyon, Oullins,…

September 18, 2017

Molecular therapy for Stroke: Fluoxetine, an anti-depressant drug, attenuates hippocampal neurons injury, augments regenerative neurogenesis after Ischemic Stroke, and ameliorates stroke damage and neurological deficits via up regulation of its target genes BDNF and NAMPT, 18/September/2017, 10.57 pm

Molecular therapy for Stroke: Fluoxetine, an anti-depressant drug, attenuates hippocampal neurons injury, augments regenerative neurogenesis after Ischemic Stroke, and ameliorates stroke damage and neurological deficits via up regulation of its target genes BDNF and NAMPT, 18/September/2017, 10.57 pm https://genomediscovery.org/wp-content/uploads/2017/09/Fluoxitine-induces-BDNF-and-NAMPT-expression-and-attenuates-stroke.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2017/09/Fluoxitine-induces-BDNF-and-NAMPT-expression-and-attenuates-stroke.jpg September 18, 2017 September 19, 2017

Introduction: What they say A recent study from Research Center for Neurobiology and Department of Neurobiology, Xuzhou Medical College, 209 Tongshan Road, Xuzhou, Jiangsu 221004, PR China; and School of Public…

September 6, 2017

Molecular therapy for muscle atrophy and wasting:Ruxolitinib (Trade name: Jakavi/Jakafi), a drug used in the treatment of Myelofibrosis, increases the expression of FGF19 and its receptor ß-Klotho, phosphorylates ERK1/2 and S6K1, decreases the expression of tumor suppressors genes, promotes regeneration of muscle cells and hypertrophy of skeletal muscle, and reverses muscular atrophy and wasting via up regulation of its target gene, 6/September/2017, 11.57 pm

Molecular therapy for muscle atrophy and wasting:Ruxolitinib (Trade name: Jakavi/Jakafi), a drug used in the treatment of Myelofibrosis, increases the expression of FGF19 and its receptor ß-Klotho, phosphorylates ERK1/2 and S6K1, decreases the expression of tumor suppressors genes, promotes regeneration of muscle cells and hypertrophy of skeletal muscle, and reverses muscular atrophy and wasting via up regulation of its target gene, 6/September/2017, 11.57 pm https://genomediscovery.org/wp-content/uploads/2017/09/Ruxolitinib-induces-FGF19-expression-and-attenuates-muscle-dystrophy.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2017/09/Ruxolitinib-induces-FGF19-expression-and-attenuates-muscle-dystrophy.jpg September 6, 2017 October 31, 2017

September 3, 2017

Regenerative therapy for muscle atrophy: Rivaroxaban (Brand name: Xarelto) increases the expression of IGF-1, PI3K(p85a) and B-Myb, decreases the expression of tumor suppressors, promotes regeneration of muscle cells, and reverses muscle atrophy via up regulation of its target gene, 04/September/2017, 1.00 am

Regenerative therapy for muscle atrophy: Rivaroxaban (Brand name: Xarelto) increases the expression of IGF-1, PI3K(p85a) and B-Myb, decreases the expression of tumor suppressors, promotes regeneration of muscle cells, and reverses muscle atrophy via up regulation of its target gene, 04/September/2017, 1.00 am https://genomediscovery.org/wp-content/uploads/2017/09/Rivaroxaban-inhibtis-muscle-dystrophy-thorugh-up-regulatin-of-IGF1-and-P13K.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2017/09/Rivaroxaban-inhibtis-muscle-dystrophy-thorugh-up-regulatin-of-IGF1-and-P13K.jpg September 3, 2017 September 3, 2017

Introduction: What they say A study from the Cardiac Regeneration and Ageing Lab, School of Life Science, Shanghai University, Shanghai 200444, China shows that “miR-29b contributes to multiple types of…

August 12, 2017

Natural product-derived therapy for muscle atrophy and wasting:Mangiferin, isolated from Mangoes (Mangefera Indica), increases the expression of FGF19 and its receptor ß-Klotho, phosphorylates ERK1/2 and S6K1, decreases the expression of tumor suppressors genes, promotes regeneration of muscle cells and hypertrophy of skeletal muscle, and reverses muscular atrophy and wasting via up regulation of its target gene, 12/August/2017, 11.18 pm

Natural product-derived therapy for muscle atrophy and wasting:Mangiferin, isolated from Mangoes (Mangefera Indica), increases the expression of FGF19 and its receptor ß-Klotho, phosphorylates ERK1/2 and S6K1, decreases the expression of tumor suppressors genes, promotes regeneration of muscle cells and hypertrophy of skeletal muscle, and reverses muscular atrophy and wasting via up regulation of its target gene, 12/August/2017, 11.18 pm https://genomediscovery.org/wp-content/uploads/2017/08/Mangiferin-increases-FGF19-expression-and-attenuates-muscle-dystrophy.jpg1_.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2017/08/Mangiferin-increases-FGF19-expression-and-attenuates-muscle-dystrophy.jpg1_.jpg August 12, 2017 August 12, 2017

July 31, 2017

Natural product-derived therapy for muscle atrophy and wasting: Capsaicin, isolated from Habanero Chilli and among others, increases the expression of FGF19 and its receptor ß-Klotho, phosphorylates ERK1/2 and S6K1, decreases the expression of tumor suppressors genes, promotes regeneration of muscle cells and hypertrophy of skeletal muscle, and reverses muscular atrophy and wasting via up regulation of its target gene, 31/July/2017, 10.22 pm

Natural product-derived therapy for muscle atrophy and wasting: Capsaicin, isolated from Habanero Chilli and among others, increases the expression of FGF19 and its receptor ß-Klotho, phosphorylates ERK1/2 and S6K1, decreases the expression of tumor suppressors genes, promotes regeneration of muscle cells and hypertrophy of skeletal muscle, and reverses muscular atrophy and wasting via up regulation of its target gene, 31/July/2017, 10.22 pm https://genomediscovery.org/wp-content/uploads/2017/07/Capsaicin-protectes-against-muscular-dystrophy-through-activation-of-FGF19-pathway.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2017/07/Capsaicin-protectes-against-muscular-dystrophy-through-activation-of-FGF19-pathway.jpg July 31, 2017 July 31, 2017

Popular Post